FR2878443B1 - Composition pharmaceutique, destinee a l'administration par voie orale de principe(s) actif(s) fortement gastro-labile(s et sa preparation - Google Patents

Composition pharmaceutique, destinee a l'administration par voie orale de principe(s) actif(s) fortement gastro-labile(s et sa preparation

Info

Publication number
FR2878443B1
FR2878443B1 FR0507582A FR0507582A FR2878443B1 FR 2878443 B1 FR2878443 B1 FR 2878443B1 FR 0507582 A FR0507582 A FR 0507582A FR 0507582 A FR0507582 A FR 0507582A FR 2878443 B1 FR2878443 B1 FR 2878443B1
Authority
FR
France
Prior art keywords
gastro
highly
preparation
pharmaceutical composition
oral administration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
FR0507582A
Other languages
English (en)
Other versions
FR2878443A1 (fr
Inventor
Abderrahim Bennis
Jean Jacques Serrano
Farid Bennis
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
LAPROPHAN, MA
Original Assignee
Promindus (Actions Promotionnelles Dans l'Industrie et le Commerce)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from FR0408564A external-priority patent/FR2873924A1/fr
Application filed by Promindus (Actions Promotionnelles Dans l'Industrie et le Commerce) filed Critical Promindus (Actions Promotionnelles Dans l'Industrie et le Commerce)
Priority to FR0507582A priority Critical patent/FR2878443B1/fr
Publication of FR2878443A1 publication Critical patent/FR2878443A1/fr
Application granted granted Critical
Publication of FR2878443B1 publication Critical patent/FR2878443B1/fr
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0007—Effervescent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
FR0507582A 2004-08-03 2005-07-18 Composition pharmaceutique, destinee a l'administration par voie orale de principe(s) actif(s) fortement gastro-labile(s et sa preparation Active FR2878443B1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
FR0507582A FR2878443B1 (fr) 2004-08-03 2005-07-18 Composition pharmaceutique, destinee a l'administration par voie orale de principe(s) actif(s) fortement gastro-labile(s et sa preparation

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0408564A FR2873924A1 (fr) 2004-08-03 2004-08-03 Composition pharmaceutique, destinee a l'administration par voie orale de principe(s) actif(s) fortement gastro-labile(s) et sa preparation
FR0507582A FR2878443B1 (fr) 2004-08-03 2005-07-18 Composition pharmaceutique, destinee a l'administration par voie orale de principe(s) actif(s) fortement gastro-labile(s et sa preparation

Publications (2)

Publication Number Publication Date
FR2878443A1 FR2878443A1 (fr) 2006-06-02
FR2878443B1 true FR2878443B1 (fr) 2009-01-16

Family

ID=36130197

Family Applications (1)

Application Number Title Priority Date Filing Date
FR0507582A Active FR2878443B1 (fr) 2004-08-03 2005-07-18 Composition pharmaceutique, destinee a l'administration par voie orale de principe(s) actif(s) fortement gastro-labile(s et sa preparation

Country Status (1)

Country Link
FR (1) FR2878443B1 (fr)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6699885B2 (en) * 1996-01-04 2004-03-02 The Curators Of The University Of Missouri Substituted benzimidazole dosage forms and methods of using same
TW200403994A (en) * 2002-04-04 2004-03-16 Bristol Myers Squibb Co Oral administration of EPOTHILONES

Also Published As

Publication number Publication date
FR2878443A1 (fr) 2006-06-02

Similar Documents

Publication Publication Date Title
NO20080827L (no) Faste doseringsformuleringer av narkotiske legemidler som har forbedret bukal adsorpsjon
EA200700049A1 (ru) Препаративные формы оральных лекарственных форм мемантина с модифицированным высвобождением
DZ3227A1 (fr) Compositions pharmaceutiques fournissant des concentrations de medicaments ameliorees
MA28514B1 (fr) Formulations pharmaceutiques pour inhalateur de poudre seche comprenant un principe actif agissant meme a faible dosage
ATE380023T1 (de) Orale feste pharmazeutische zusammensetzungen zur ph-abhängig mehrphasigen freisetzung
HK1096034A1 (en) A solid dosage form comprising a fibrate
HUP0302319A3 (en) Pharmaceutical composition for oral administration of active ingredient
AR023972A1 (es) Composiciones de medicamentos a base de compuestos anticolinergicamente activos y beta-mimeticos
NO20020976L (no) Retarderte, orale, farmasöytiske administreringsformer
DE69906518D1 (de) Arzneistoff-abgabesystem enthaltend eine festgepackte, feste arzneistoffbasis
EP2248519A3 (fr) Formes galéniques de film non mucoadhésifs
DE60313359D1 (de) Fenofibratsäure enthaltende pharmazeutische zusammensetzung und deren physiologisch verträgliche salze und derivate
DE69940557D1 (de) Ein hydrokolloid und einen celluloseether enthaltende tablette mit verzögerter freisetzung
BG66093B1 (bg) Състави с контролирано освобождаване, съдържащи нимесулид
AU2003215245A8 (en) Conjugates of biologically active compounds, methods for their preparation and use, formulation and pharmaceutical applications thereof
DE602004011398D1 (de) Direkt komprimierbare pharmazeutische zusammensetzung für die orale verabreichung von cci-779
DE60020501D1 (de) Trimetazidinhaltige Matrixtablette zur verlängerten Wirkstofffreisetzung nach oraler Gabe
ATA59499A (de) Pharmazeutische, tolperison enthaltende zubereitung zur oralen verabreichung
ATE288766T1 (de) Pharmazeutische zusammensetzungen zur oralen und topischen verabreichung
DK1401405T3 (da) Orale, farmaceutiske sammensætninger med forbedret biotilgængelighed
MA28862B1 (fr) Composition pharmaceutique sous forme de comprime a residence gastrique contenant un principe actif
DE60124144D1 (de) Pharmazeutische zusammenstellungen zur verstärkung der artzneimitteleffekte
TN2010000008A1 (en) Oral pharmaceutical solutions containing telbivudine
ATE460934T1 (de) Pharmazeutische zubereitungen von ciprofloxacin
FR2878443B1 (fr) Composition pharmaceutique, destinee a l'administration par voie orale de principe(s) actif(s) fortement gastro-labile(s et sa preparation

Legal Events

Date Code Title Description
PLFP Fee payment

Year of fee payment: 12

PLFP Fee payment

Year of fee payment: 13

PLFP Fee payment

Year of fee payment: 14

PLFP Fee payment

Year of fee payment: 16

PLFP Fee payment

Year of fee payment: 17

PLFP Fee payment

Year of fee payment: 18

TP Transmission of property

Owner name: LAPROPHAN, MA

Effective date: 20230505

PLFP Fee payment

Year of fee payment: 19

PLFP Fee payment

Year of fee payment: 20